Thelansis’s "Advanced Parkinson's Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Parkinson's Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced Parkinson's Disease is a late-stage progression of this neurodegenerative disorder, with a multifaceted interplay of motor and non-motor impairment that severely impairs quality of life and daily activities. With additional loss of dopaminergic neurons in the substantia nigra, patients have more severe motor fluctuations, dyskinesias, freezing of gait, postural instability, and risk of falls, usually making them dependent on caregivers. Non-motor features—cognitive impairment, hallucinations, autonomic dysfunction, sleep disturbances, and mood disorders—take over and become refractory to conventional therapies, making treatment more difficult. Levodopa is still the mainstay of therapy, but decreasing efficacy and side effects at advanced stages make it necessary to use adjunctive measures, such as dopamine agonists, MAO-B inhibitors, and device-based approaches like DBS or levodopa-carbidopa intestinal gel infusion. Multidisciplinary care in neurology, physical therapy, psychiatry, and palliative care is needed to meet the changing needs of patients and caregivers. The course of the disease is very unpredictable, and goal-oriented individualized treatment is essential to preserve autonomy, avoid complications, and preserve dignity in the face of progressive impairment.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Advanced Parkinson’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034 report
Our team will get in touch with you shortly about the Advanced Parkinson’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034 report.